Radiation-Induced Lumbosacral Plexopathy Medication
- Author: Rajesh R Yadav, MD; Chief Editor: Robert H Meier III, MD more...
Medication Summary
Tricyclic antidepressants (TCAs), such as amitriptyline, may be used in lower doses. The use of antiepileptics may be helpful.
Tricyclic antidepressants
Class Summary
TCAs have central and peripheral anticholinergic effects, as well as sedative effects, and block the active reuptake of norepinephrine and serotonin. The multifactorial mechanism of analgesia may include improved sleep, an altered perception of pain, and an increase in pain threshold. The efficacy of these drugs can be potentiated with the concomitant use of opiates and nonsteroidal anti-inflammatory drugs (NSAIDs). Rarely should these drugs be used in the treatment of acute pain, since a few weeks may be required for them to become effective.
Amitriptyline (Elavil)
Analgesic for certain chronic and neuropathic pain. Amitriptyline has the most anticholinergic side effects of all drugs in this category.
Antiepileptic drugs
Class Summary
These drugs stabilize neuronal membranes and reduce neuronal hyperexcitability. The analgesic effect may be due to such stabilization and control of hyperexcitability, because aberrant electrical activity has been recorded with neuropathic pain.
Gabapentin (Neurontin)
Has anticonvulsant properties and antineuralgic effects; however, the exact mechanism of action is unknown. Gabapentin is structurally related to GABA but does not interact with GABA receptors.
Carbamazepine (Tegretol)
Used typically for generalized tonic-clonic seizures and partial seizures, as well as for trigeminal neuralgia. Plasma levels are between 4-12 mcg/mL for analgesic and antiseizure response.
Valproic acid (Depakene)
Generally indicated for absence seizures and generalized tonic-clonic seizures. Some relief may be noted with neuropathic pain, especially the lancinating type.
Corticosteroids
Class Summary
Glucocorticoids have anti-inflammatory, hormonal, and metabolic effects. Inflammation is suppressed with the blockage of phospholipase A2, which inhibits the formation of arachidonic acid and, thus, the prostaglandins. The analgesic effect may be due to the anti-inflammatory activity, with a decrease in edema.
Dexamethasone (Decadron, AK-Dex)
For various allergic and inflammatory diseases. Dexamethasone decreases inflammation by suppressing the migration of polymorphonuclear leukocytes and by reducing capillary permeability.
Analgesics
Class Summary
These drugs are generally used for short-term, acute pain that is moderate to severe in nature, as well as for chronic pain (eg, cancer). They provide analgesia without antipyretic or anti-inflammatory action. The mechanism of action is the inhibition of nociceptive impulses at the dorsal horn of the spinal cord and at supraspinal sites due to interaction with opiate receptors. Structural derivatives of GABA are also used in the management of neuropathic pain.
Pregabalin (Lyrica)
Structural derivative of GABA. Pregabalin's mechanism of action is unknown. This agent binds with high affinity to the alpha2 -delta site (a calcium channel subunit). In vitro, pregabalin reduces the calcium-dependent release of several neurotransmitters, possibly by modulating calcium channel function. It is FDA approved for neuropathic pain associated with diabetic peripheral neuropathy or postherpetic neuralgia and as an adjunctive therapy in partial-onset seizures.
Methadone (Dolophine)
Used in the management of severe pain. Methadone inhibits ascending pain pathways, diminishing the perception of and response to pain.
Morphine sulfate (Duramorph, MS Contin, Astramorph)
Available in immediate (3-4 h duration) and extended release preparation (12 h). Switch over to long-acting preparations (MS Contin) once pain is controlled with short-acting preparation (MS IR). Morphine can produce drug dependence and has the potential for being abused. Tolerance may develop with repeated exposure. Abrupt cessation or sudden reduction in dose with prolonged use may result in withdrawal symptoms. Physical dependence is not of paramount importance in terminally ill patients.
Pettigrew LC, Glass JP, Maor M, et al. Diagnosis and treatment of lumbosacral plexopathies in patients with cancer. Arch Neurol. Dec 1984;41(12):1282-5. [Medline].
Ashenhurst EM, Quartey GR, Starreveld A. Lumbo-sacral radiculopathy induced by radiation. Can J Neurol Sci. Nov 1977;4(4):259-63. [Medline].
Jaeckle KA, Young DF, Foley KM. The natural history of lumbosacral plexopathy in cancer. Neurology. Jan 1985;35(1):8-15. [Medline].
Abu-Rustum NR, Rajbhandari D, Glusman S, et al. Acute lower extremity paralysis following radiation therapy for cervical cancer. Gynecol Oncol. Oct 1999;75(1):152-4. [Medline].
Iglicki F, Coffin B, Ille O, et al. Fecal incontinence after pelvic radiotherapy: evidences for a lumbosacral plexopathy. Report of a case. Dis Colon Rectum. Apr 1996;39(4):465-7. [Medline].
Jaeckle KA. Neurological manifestations of neoplastic and radiation-induced plexopathies. Semin Neurol. Dec 2004;24(4):385-93. [Medline].
Jaeckle KA. Neurologic manifestations of neoplastic and radiation-induced plexopathies. Semin Neurol. Jul 2010;30(3):254-62. [Medline].
Ozkavukcu E, Cayli E, Yagci C, et al. Ruptured iliac aneurysm presenting as lumbosacral plexopathy. Diagn Interv Radiol. Mar 2008;14(1):26-8. [Medline]. [Full Text].
Abdellaoui A, West NJ, Tomlinson MA, et al. Lower limb paralysis from ischaemic neuropathy of the lumbosacral plexus following aorto-iliac procedures. Interact Cardiovasc Thorac Surg. Aug 2007;6(4):501-2. [Medline]. [Full Text].
Moskovic E, Curtis S, A'Hern RP, et al. The role of diagnostic CT scanning of the brachial plexus and axilla in the follow-up of patients with breast cancer. Clin Oncol (R Coll Radiol). Mar 1992;4(2):74-7. [Medline].
Taylor BV, Kimmel DW, Krecke KN. Magnetic resonance imaging in cancer-related lumbosacral plexopathy. Mayo Clin Proc. Sep 1997;72(9):823-9. [Medline].
Wilbourn AJ. Electrodiagnosis of plexopathies. Neurol Clin. Aug 1985;3(3):511-29. [Medline].
Masakado Y, Kawakami M, Suzuki K, et al. Clinical neurophysiology in the diagnosis of peroneal nerve palsy. Keio J Med. Jun 2008;57(2):84-9. [Medline].
Pritchard J, Anand P, Broome J, et al. Double-blind randomized phase II study of hyperbaric oxygen in patients with radiation-induced brachial plexopathy. Radiother Oncol. Mar 2001;58(3):279-86. [Medline].
Enevoldson TP, Scadding JW, Rustin GJ, et al. Spontaneous resolution of a postirradiation lumbosacral plexopathy. Neurology. Nov 1992;42(11):2224-5. [Medline].
Bradley WG, Fewings JD, Cumming WJ, et al. Delayed myeloradiculopathy produced by spinal X-irradiation in the rat. J Neurol Sci. Jan-Feb 1977;31(1):63-82. [Medline].
Cavanagh JB. Prior x-irradiation and the cellular response to nerve crush: duration of effect. Exp Neurol. Oct 1968;22(2):253-8. [Medline].
Dahele M, Davey P, Reingold S, et al. Radiation-induced lumbo-sacral plexopathy (RILSP): an important enigma. Clin Oncol (R Coll Radiol). Jun 2006;18(5):427-8. [Medline].
Glantz MJ, Burger PC, Friedman AH. Treatment of radiation-induced nervous system injury with heparin and warfarin. Neurology. Nov 1994;44(11):2020-7. [Medline].
Stryker JA, Sommerville K, Perez R, et al. Sacral plexus injury after radiotherapy for carcinoma of cervix. Cancer. Oct 1 1990;66(7):1488-92. [Medline].
Stubgen JP. Neuromuscular disorders in systemic malignancy and its treatment. Muscle Nerve. Jun 1995;18(6):636-48. [Medline].
Thomas JE, Cascino TL, Earle JD. Differential diagnosis between radiation and tumor plexopathy of the pelvis. Neurology. Jan 1985;35(1):1-7. [Medline].

